Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 6Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Ganglioneuroblastoma 2Burkitt Lymphoma 2Blast Crisis 2Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Osteosarcoma 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Razoxane 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Extravasation × Razoxane × Clear all
NCT00548704 2015-10-21

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Valerio Therapeutics

Phase 2/3 Completed
57 enrolled

Extravasation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡